Psioxus Therapeutics

Psioxus Therapeutics

Psioxus Therapeutics

Immuno-oncology specialists with a clinical stage oncolytic virus program and the T-SIGn plaform for immuno-gene-therapy
Founded
2010
Raised
$73.4M
Follow us
Featured on
Alexa global traffic share
Twitter followers
Latest funding
$39,241,539
Venture capital (Series C) - 2015
$34,118,753
Venture capital (Series B) - 2012
Team Size
10+
Employees

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Psioxus Therapeutics makes some noise.